Key Points
- Director Rehan Verjee bought 972 Tyra Biosciences shares at an average price of $20.58, investing approximately $20,004 and increasing his ownership to 972 shares.
- Tyra shares were trading at $22.03 after a 6.4% decline, while the company reported a quarterly loss of $0.69 per share, missing analyst expectations of a $0.65 loss.
- Institutional investors own 84.14% of the stock, and analysts maintain a broadly positive outlook with a “Moderate Buy” consensus and an average price target of $47.88, despite mixed clinical updates and recent target reductions.
Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Rehan Verjee acquired 972 shares of the company's stock in a transaction that occurred on Wednesday, September 9th. The shares were acquired at an average price of $20.58 per share, for a total transaction of $20,003.76. Following the purchase, the director owned 972 shares of the company's stock, valued at $20,003.76. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Tyra Biosciences Trading Down 6.4%
NASDAQ:TYRA opened at $22.03 on Friday. The stock has a 50 day moving average of $28.39 and a 200-day moving average of $31.84. The firm has a market capitalization of $1.31 billion, a PE ratio of -9.18 and a beta of 0.73. Tyra Biosciences, Inc. has a 52 week low of $11.82 and a 52 week high of $40.65.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts predict that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.
Institutional Trading of Tyra Biosciences
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC purchased a new position in shares of Tyra Biosciences in the second quarter worth approximately $943,000. WINTON GROUP Ltd acquired a new stake in shares of Tyra Biosciences in the second quarter worth $537,000. Engineers Gate Manager LP acquired a new stake in shares of Tyra Biosciences in the second quarter worth $1,021,000. Squarepoint Ops LLC boosted its position in shares of Tyra Biosciences by 211.3% in the second quarter. Squarepoint Ops LLC now owns 63,805 shares of the company's stock worth $2,038,000 after buying an additional 43,311 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Tyra Biosciences by 55,815.5% during the second quarter. California State Teachers Retirement System now owns 783,935 shares of the company's stock valued at $24,544,000 after buying an additional 782,533 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.
More Tyra Biosciences News
Here are the key news stories impacting Tyra Biosciences this week:
- Positive Sentiment: Initial SURF302 results support further development of dabogratinib in bladder cancer, providing evidence of potential activity for Tyra’s lead program. The Pharma Letter article
- Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, signaling substantial potential upside if the clinical program succeeds. Benzinga analyst rating report
- Positive Sentiment: Director Rehan Verjee purchased 972 shares for approximately $20,004 at an average price of $20.58. The insider purchase may be viewed as a signal of confidence, although its size is modest relative to the company’s market value. SEC insider ownership filing
- Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the figures appear anomalous and provide little useful information about trading sentiment.
- Negative Sentiment: Coverage indicated that bladder-cancer response rates from SURF302 were below investor expectations, creating uncertainty about dabogratinib’s commercial and regulatory potential. BioSpace article
- Negative Sentiment: HC Wainwright lowered its price target from $45 to $30, although it retained a “Buy” rating, reflecting reduced near-term expectations following the trial update. Benzinga analyst rating report
- Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of TYRA investors, adding a legal and reputational overhang. The announcement did not establish wrongdoing by Tyra. Pomerantz investor alert
Analysts Set New Price Targets
TYRA has been the topic of a number of recent analyst reports. Bank of America boosted their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. JonesTrading started coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They issued a "buy" rating and a $56.00 price target on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Tyra Biosciences in a report on Friday, July 17th. Cantor Fitzgerald restated an "overweight" rating on shares of Tyra Biosciences in a research report on Thursday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $47.88.
View Our Latest Analysis on TYRA
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
